Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (symbol: BLCO) is a prominent player in the vision care industry based in Madrid, Spain. Originally part of Bausch Health, Bausch + Lomb became a public company in 2022. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals.
Vision Care Segment: This segment covers contact lenses and ocular health products. Bausch + Lomb holds a 10% market share in contact lenses, and its portfolio includes popular brands such as Biotrue and Lumify.
Surgical Segment: This includes intraocular lenses and equipment for cataract and vitreoretinal surgeries. The company also provides a range of surgical instruments, making it a comprehensive provider in the surgical eye care market.
Ophthalmic Pharmaceuticals: Bausch + Lomb offers over 100 products, including Xipere, Vyzulta, and Lotemax, which are designed to treat various eye conditions. This extensive lineup makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market.
With a strong commitment to innovation and quality, Bausch + Lomb continuously works on new projects and partnerships to enhance its product offerings. The company’s diverse portfolio and strategic initiatives ensure its significant role in the vision care industry.
Bausch + Lomb (NYSE/TSX: BLCO) announced its ONE by ONE and Biotrue Eye Care Recycling programs have won the gold award for 'Most Environmentally Friendly Service of the Year' at the 2022 Best in Biz Awards. Joe Gordon, president of Global Consumer, emphasized the company's commitment to sustainability, highlighting progress in recycling over 60 million used contact lenses and eye care materials. These programs aim to address plastic pollution by enabling the proper recycling of items typically not accepted in standard facilities.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced that its new contact lens solution, Biotrue Hydration Plus, has won the 2022 BIG Awards for Business Product of the Year from Business Intelligence Group. This innovative solution enhances moisture retention for contact lens wearers, providing all-day comfort and exceptional disinfection with a triple disinfectant system. It incorporates bio-inspired ingredients, including 25% more hyaluronan, potassium, and erythritol, to match the pH of healthy tears, addressing the needs of patients suffering from contact lens dryness.
Bausch + Lomb (NYSE/TSX: BLCO) has announced that its innovative recycling programs, ONE by ONE and Biotrue Eye Care, have successfully collected over 58 million units (approximately 356,723 pounds) of used contact lenses and related materials since their inception. This effort, in collaboration with TerraCycle, helps reduce environmental pollution caused by non-biodegradable plastics in the U.S. The ONE by ONE program has been active since November 2016, while the Biotrue program began in April 2021. These initiatives highlight Bausch + Lomb's commitment to sustainability.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will participate in the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:40 a.m. ET. The event will feature CEO Joseph C. Papa and CFO Sam Eldessouky. A webcast of the presentation will be available on the company's Investor Relations page.
Founded in 1853, Bausch + Lomb is a global leader in eye health, offering over 400 products, including contact lenses and ophthalmic pharmaceuticals. The company is headquartered in Vaughan, Ontario, with a significant global presence.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) reported third-quarter 2022 revenues of $942 million, a 1% decline year-over-year, impacted by $55 million in foreign exchange losses. Adjusted EBITDA was $187 million, down from $207 million in 2021. The net loss attributable to the company was $18 million, compared to a net income of $60 million the previous year. Despite challenges, organic revenue grew 5%, driven by strong performance in all segments. The company revised its full-year 2022 guidance due to currency headwinds, with revised revenues expected between $3.70 billion and $3.75 billion.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched Project Watson, a new line of health care products for dogs in the U.S., aimed at enhancing their eye, ear, and overall wellbeing. Developed in collaboration with veterinarians, products include eye wash, eyelid wipes, ear wash, ear wipes, and health supplements targeting eye health and general health. The rollout begins in November 2022 at major retailers like Chewy and Walmart, contributing to Bausch + Lomb's longstanding commitment to pet care and addressing unmet health needs in pets.
Bausch + Lomb Corporation (BLCO) announced its participation in the American Academy of Optometry meeting from Oct. 26-29, 2022, in San Diego. The company will present four scientific posters highlighting its Biotrue Hydration Plus Multi-Purpose Solution, which offers enhanced moisture for contact lens wearers. CEO Joseph C. Papa emphasized the solution's benefits for eye care professionals and patients. Additionally, Bausch + Lomb will sponsor nine educational events focusing on various eye health topics, including dry eye disease and the latest clinical data.
Bausch + Lomb (NYSE/TSX: BLCO) will announce its third-quarter 2022 financial results on November 2, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow, providing insights and updates on the company's performance. Interested parties can access the webcast on the company's website. Bausch + Lomb, a global leader in eye health with over 400 products, continues to focus on enhancing vision care and maintaining a strong market presence in nearly 100 countries.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched an enhanced version of its Ocuvite Adult 50+ eye vitamin, now featuring 30 micrograms of vitamin D. This antioxidant aims to support healthy cell function and protect eye health, especially as aging can weaken the eyes’ natural defenses against daily stressors like screens and sunlight. The new formulation will replace the existing Ocuvite Adult 50+ and will be available in stores from October 2022 at a retail price of $12.85 for a 50-count bottle.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
What does Bausch + Lomb Corporation do?
When did Bausch + Lomb become a public company?
What are the primary segments Bausch + Lomb operates in?
What are some key products in Bausch + Lomb's vision care segment?
What does Bausch + Lomb offer in its surgical segment?
What products are included in Bausch + Lomb's ophthalmic pharmaceuticals segment?
Where is Bausch + Lomb Corporation headquartered?
What market share does Bausch + Lomb hold in the contact lenses market?
What makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market?
What is Bausch + Lomb's commitment towards its products and services?
